Iovance Biotherapeutics, Inc.
IOVA
$2.64
-$0.05-1.86%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
6/29/2025
-
MarketBeat
1/22/2026
-
GuruFocus
1/21/2026
-
Simply Wall St
1/19/2026
-
GuruFocus
1/18/2026
-
Simply Wall St
1/16/2026
-
GuruFocus
1/16/2026
-
GuruFocus
1/16/2026
-
Globe Newswire
1/16/2026
-
Fool.com Headlines
1/16/2026
-
Simply Wall St
1/16/2026
-
TipRanks Financial Blog
1/15/2026
-
Insider Monkey
1/13/2026
-
Simply Wall St
1/12/2026
-
Globe Newswire
1/12/2026
-
MarketBeat
1/10/2026
-
Simply Wall St
1/8/2026
-
MarketBeat
1/2/2026
-
Ticker Report
1/2/2026
-
MarketBeat
12/31/2025
-
Yahoo! Finance: News
12/29/2025
-
Insider Monkey
12/29/2025
-
Fool.com Headlines
12/29/2025
-
Seeking Alpha - Long Ideas
12/29/2025
-
SeekingAlpha
12/29/2025
-
SeekingAlpha.com: Most Popular Articles
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 260 7120
Address
825 Industrial Road
San Carlos, CA 94070
San Carlos, CA 94070
Country
Year Founded
Business Description
Sector
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of...
more